DTC.F Defence Therapeutics Inc.

Healthcare Biotechnology Frankfurt Exchange
0.1930 EUR
Close of Nov 11, 2026
0.1610 0.5940
Market cap
EUR 14.7M
P/E
-
P/B
6.89x
ROE
-154.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is DTC.F undervalued?

Graham number

The Graham number of Defence Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Defence Therapeutics Inc. fundamental analysis

No fundamental analysis for Defence Therapeutics Inc. yet.

Defence Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Defence Therapeutics Inc.

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical stu…

Full company profile